Table 2.
Characteristics of ceftaroline therapies at the start of administration.
| Variable | No. of Patients a | % | 95% CI |
|---|---|---|---|
| Type of therapy | |||
| Empirical therapy | 179/200 | 90 | 84–93 |
| Targeted therapy b | 21/200 | 10 | 7–16 |
| First-line therapy | 103/200 | 52 | 44–59 |
| Salvage therapy | 97/200 | 48 | 41–56 |
| On-label therapy | 186/200 | 93 | 89–96 |
| Off-label therapy | 14/200 | 7 | 4–11 |
| Monotherapy | 193/200 | 97 | 93–98 |
| Combination therapy c | 7/200 | 3 | 2–7 |
| Indications for empirical therapy d | |||
| Sepsis | 5/179 | 3 | 1–6 |
| CAP in patients without COVID-19 | 7/179 | 4 | 2–8 |
| CAP in patients with COVID-19 | 165/179 | 92 | 87–95 |
| Skin and soft tissue infection | 2/179 | 1 | 0–4 |
| Endocarditis | 1/179 | 1 | 0–3 |
| Other e | 2/179 | 1 | 0–4 |
| Indications for targeted therapy d | |||
| BSI | 16/21 | 76 | 55–90 |
| CAP in patients without COVID-19 | 8/21 | 38 | 20–60 |
| CAP in patients with COVID-19 | 0/21 | 0 | 0–20 |
| Skin and soft tissue infection | 6/21 | 29 | 13–51 |
| Endocarditis | 5/21 | 24 | 10–46 |
| Other f | 6/21 | 29 | 13–51 |
BSI, bloodstream infection; CAP, community acquired pneumonia; CI, confidence intervals; COVID-19, coronavirus disease 2019; HAP, hospital-acquired pneumonia; IQR, interquartile range; VAP, ventilator-associated pneumonia. a Results are presented as No. of patients/Total of patients unless otherwise indicated; b Post-identification of the causative agent; c With other agents with anti-MRSA activity: daptomycin (n = 7); d Not mutually exclusive; e HAP (n = 1), septic arthritis (n = 1), f HAP (n = 1), osteomyelitis (n = 1), pleural empyema (n = 1), VAP (n = 1), vertebral osteomyelitis (n = 2).